AMGN Company Profile and Key Details

Q: Who are the executives of AMGN?

Mr. Arvind SoodVice President of Investor RelationsMr. Jonathan P. GrahamExecutive Vice President, Gen. Counsel & Sec.Dr. David M. Reese M.D.Executive Vice President of R&DMr. Mike ZahigianSenior Vice President & Chief Information OfficerMr. Robert A. BradwayChairman, Chief Executive Officer & PresMr. Murdo GordonExecutive Vice President of Global Commercial OperationsMs. Linda H. LouieVice President of Fin. & Chief Accounting OfficerMr. Esteban SantosExecutive Vice President of OperationsMs. Nancy A. GrygielSenior Vice President of Worldwide Compliance & Bus. Ethics and Chief Compliance OfficerMr. Peter H. GriffithExecutive Vice President & Chief Financial Officer

NASDAQ : AMGN

Amgen

$367.80

1.6+0.44%

At Close 4:00 PM

63.65

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Amgen Inc. (AMGN) stock surged +0.44%, trading at $367.80 on NASDAQ, up from the previous close of $366.20. The stock opened at $365.73, fluctuating between $365.03 and $374.90 in the recent session.

Stock Snapshot

366.2

Prev. Close

198.05B

Market Cap

365.03

Day Low

25.85

P/E Ratio

14.23

EPS (TTM)

13.76

Cash Flow per Share

365.73

Open

538.48M

Number of Shares

374.9

Day High

99.75%

Free Float in %

11.65

Book Value

3.79M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 05, 2026	365.73	374.90	365.00	367.80	3.98M
Feb 04, 2026	352.03	368.74	342.38	366.20	5.88M
Feb 03, 2026	341.24	349.50	338.59	338.59	4.02M
Feb 02, 2026	339.47	345.98	339.41	344.68	1.9M
Jan 30, 2026	340.81	345.50	338.07	341.88	2.5M
Jan 29, 2026	341.66	347.27	338.75	342.94	3.14M
Jan 28, 2026	349.00	351.95	340.00	342.22	2.34M
Jan 27, 2026	348.57	353.25	346.93	351.32	3.16M
Jan 26, 2026	344.70	350.43	343.62	349.69	3.11M
Jan 23, 2026	346.18	349.23	341.82	344.75	2.02M
Jan 22, 2026	344.15	349.98	342.14	347.07	3.02M
Jan 21, 2026	329.95	343.98	329.32	343.60	4.03M
Jan 20, 2026	325.58	331.34	321.71	331.00	2.88M
Jan 16, 2026	328.70	333.03	326.90	330.41	3.99M
Jan 15, 2026	328.97	332.50	325.19	330.03	2.47M
Jan 14, 2026	324.09	329.20	323.55	328.97	1.86M
Jan 13, 2026	327.42	327.75	319.86	324.30	2.33M
Jan 12, 2026	328.47	328.47	322.74	325.54	2.46M
Jan 09, 2026	328.81	332.08	323.89	326.10	2.12M
Jan 08, 2026	337.76	341.46	328.21	330.11	2.8M

Contact Details

Thousand Oaks, CA 91320-1799

United States

https://www.amgen.com 805 447 1000

About Company

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh�et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Stock Peers

AZN

-0.29-0.15%

AstraZeneca PLC$187.16 BIIB

-0.09-0.05%

Biogen Inc.$185.36 GILD

3.14+2.15%

Gilead Sciences, Inc.$149.37 HZNP

Horizon Therapeutics Public Limited Company$116.30 SNY

-0.59-1.23%

Sanofi$47.49 GRFS

-0.35-3.67%

Grifols, S.A.$9.19 SCLX

-0.89-10.17%

Scilex Holding Company$7.86 MIRA

-0.08-6.61%

MIRA Pharmaceuticals, Inc.$1.13 CTOR

-0.04-3.48%

Citius Oncology, Inc.$1.11 SCLXW

-0.0119-7.83%

Scilex Holding Company$0.14

Company Overview

Amgen Inc. (NASDAQ:AMGN) closed at $367.80 USD, gaining $1.60 (0.44%) from the previous close of $366.20. The stock is currently within 5% of its 52-week high $261.43 and $374.90. With a market capitalization of about $198.05 billion, Amgen Inc. is classified as a large-cap and shows lower-than-market volatility (beta ~0.47). Key stats such as the average daily volume over the past year has been around 2.91 million shares, in line with its 52-week average. Headquartered in Thousand Oaks, CA, Amgen Inc. operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Robert A. Bradway, the company employs approximately 28,000 people and listed since June 17, 1983. Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 8.06%, SMA50 10.02%, SMA200 21.62%). The stock’s 14-day RSI is 69.64 (firm momentum), while the ATR of 9.67 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -0.26% below its high and over 40.69% above its low. Average 10-day trading volume of 3.37 million shares is slightly above the 3-month average of 2.85 million, indicating heightened recent market interest.

Valuation Metrics

Amgen Inc. trades at a P/E ratio of 25.62, slightly below the S&P 500 average, with a price-to-sales ratio of 5.37 and a price-to-book ratio of 22.82 reflecting a rich premium to book value. The P/FCF stands at 24.36, also above market averages. Compared to sector medians, Amgen Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Amgen Inc. last paid a dividend of 9.52 per share, this equals a trailing yield of roughly 2.71%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $906.93. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Amgen Inc. generated EPS of $14.23 over the past year. Five-year average earnings growth is 2.94%. Wall Street analysts project EPS growth of 3.35% annually over the next five years. The latest quarter delivered EPS of $5.64. The next quarter is forecast at $4.83. Next year's EPS is expected at $8.03. Analyst sentiment is neutral. Analyst rating data shows there are 7 Strong Buy ratings, 2 Buy ratings, 19 Hold ratings, 0 Sell rating and 4 Strong Sell ratings. Price targets range from $390.00 to $261.00. The high target offers 6.04% upside. The low target suggests -29.04% downside. The mean target is $324.44. This offers -11.79% upside. Amgen Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 04, 2025, missed forecasts by 12.35%. The prior quarter beat by 14.02%. Over the last six quarters, Apple has recorded several small beats. These include -0.2% in August 06, 2024.

Shareholding & Insider Activity

Amgen Inc. has 538.48 million shares outstanding. The public float is 537.12 million shares, elevated short interest at 2.60% of float. This equals 13.96 million shares. The short ratio is 5.1 days. Institutional investors hold 84.04% of the float. Insiders own 0.21%. AMGEN INC holds 35.37 million shares, Bradway Robert A has 383.10 thousand shares and Santos Esteban has 71.55 thousand shares. Over the past six months, insider transactions show net selling. They sold 10.68 thousand shares across 4 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Amgen generated $33.42B in revenue, or $61.78 per share. Gross margin was 61.53%, operating margin 21.71%, and net profit margin 12.24%. Returns are modest, with ROA at 4.21% and ROE at 65.63%.
On valuation metrics, Amgen trades at a P/E of 25.62, P/S of 5.37 and P/B of 22.82. The current ratio is 1.14 and quick ratio is 0.90. Operationally, the company’s inventory turnover is 1.74 and cash conversion cycle is -398.22 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 6.31, supported by a cash flow-to-debt ratio of 0.18.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2024, Amgen posted revenue of $33.42B, down slightly from $28.19B in the prior quarter. Gross profit was $20.57B (margin 61.53%). Operating income was $7.26B (margin 21.7%). Net income was$4.09B (EPS $7.62).
The company ended the quarter with $10.94B in cash and short-term investments, a total debt of $64.61B, and net debt of $53.67B. Total assets were $97.15B, with equity of $6.23B. Financials further reflected stability, with operating cash flow of $8.47B, free cash flow of $7.36B, and capital expenditures of - $1.11B.

Price Forecast & Outlook

Our AI price prediction model suggests that Amgen Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.34%, with price expected at $369.05 by February 19, 2026, within a range of $362.83 to $375.09 3-Month Outlook: Projected fall of -8.55%, reaching $336.35 by May 06, 2026, with a range of $326.88 to $348.15. 1-Year Outlook: Projected gain of 6.58%, with price at $392.00 by February 05, 2027, within a range of $384.55 to $400.20.

Key Takeaways

Amgen Inc. (NASDAQ:AMGN) shares are flat 1.13% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Amgen Inc. trading at a premium to the broader market with a P/E of 25.62. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $295.11, suggesting -19.76% downside. Our AI forecast model points to short-term strength (0.34% over two weeks), a medium-term fall (-8.55% over three months), and a longer-term gain (6.58% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Amgen Inc. (AMGN) stock price?

Amgen Inc. (NASDAQ: AMGN) stock price is $367.80 in the last trading session. During the trading session, AMGN stock reached the peak price of $374.90 while $365.03 was the lowest point it dropped to. The percentage change in AMGN stock occurred in the recent session was 0.44% while the dollar amount for the price change in AMGN stock was $1.60.

AMGN's industry and sector of operation?

The NASDAQ listed AMGN is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Amgen Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of AMGN?

Mr. Arvind Sood
Vice President of Investor Relations
Mr. Jonathan P. Graham
Executive Vice President, Gen. Counsel & Sec.
Dr. David M. Reese M.D.
Executive Vice President of R&D
Mr. Mike Zahigian
Senior Vice President & Chief Information Officer
Mr. Robert A. Bradway
Chairman, Chief Executive Officer & Pres
Mr. Murdo Gordon
Executive Vice President of Global Commercial Operations
Ms. Linda H. Louie
Vice President of Fin. & Chief Accounting Officer
Mr. Esteban Santos
Executive Vice President of Operations
Ms. Nancy A. Grygiel
Senior Vice President of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer
Mr. Peter H. Griffith
Executive Vice President & Chief Financial Officer

How AMGN did perform over past 52-week?

AMGN's closing price is 40.69% higher than its 52-week low of $261.43 where as its distance from 52-week high of $374.90 is -1.89%.

How many employees does AMGN have?

Number of AMGN employees currently stands at 28,000.

Link for AMGN official website?

Official Website of AMGN is: https://www.amgen.com

How do I contact AMGN?

AMGN could be contacted at phone 805 447 1000 and can also be accessed through its website. AMGN operates from One Amgen Center Drive, Thousand Oaks, CA 91320-1799, United States.

How many shares of AMGN are traded daily?

AMGN stock volume for the day was 3.79M shares. The average number of AMGN shares traded daily for last 3 months was 2.91M.

What is the market cap of AMGN currently?

The market value of AMGN currently stands at $198.05B with its latest stock price at $367.80 and 538.48M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	28000
Beta	0.45
Sales or Revenue	$33.42B
5Y Sales Change%	0.467%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

AMGN Company Profile and Key Details

Amgen

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Valuation Metrics

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways